2024
A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection
Mayer D, Nelson M, Andriyanova D, Filler R, Ökten A, Antao O, Chen J, Scumpia P, Weaver W, Wilen C, Deshayes S, Weinstein J. A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection. Journal Of Controlled Release 2024, 370: 570-582. PMID: 38734312, PMCID: PMC11665867, DOI: 10.1016/j.jconrel.2024.05.008.Peer-Reviewed Original ResearchAntigen delivery platformGerminal centersCD4<sup>+</sup> T follicular helper (Tfh) cellsT follicular helper (Tfh) cellsAdaptive immune cell responsesOptimal adaptive immune responsesAnti-receptor binding domain antibodiesInfluenza virus challengeRobust neutralizing antibodiesImmune cell responsesEnhanced neutralizing antibodiesAdaptive immune responsesDelivery platformAntibody mediated immunityLymph nodesVaccine platformNeutralizing antibodiesHumoral immunitySARS-CoV-2 spike proteinSustained release profileTarget antigenImmune responseVirus challengeViral infectionCell responsesKeratin 17 modulates the immune topography of pancreatic cancer
Delgado-Coka L, Horowitz M, Torrente-Goncalves M, Roa-Peña L, Leiton C, Hasan M, Babu S, Fassler D, Oentoro J, Bai J, Petricoin E, Matrisian L, Blais E, Marchenko N, Allard F, Jiang W, Larson B, Hendifar A, Chen C, Abousamra S, Samaras D, Kurc T, Saltz J, Escobar-Hoyos L, Shroyer K. Keratin 17 modulates the immune topography of pancreatic cancer. Journal Of Translational Medicine 2024, 22: 443. PMID: 38730319, PMCID: PMC11087249, DOI: 10.1186/s12967-024-05252-1.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaCD8+ T cellsT cellsK17 expressionCell carcinomaPatient survivalMolecular subtypes of pancreatic ductal adenocarcinomaIntratumoral CD8+ T cellsSpatial distribution of T cellsKeratin 17CD8+ T cell abundanceImmune responseSubtype of pancreatic ductal adenocarcinomaCervical squamous cell carcinomaAssociated with decreased numbersCD16+ macrophagesTumor-intrinsic variablesDistribution of T cellsLymph node statusSquamous cell carcinomaBasal cell carcinomaCD163+ macrophagesT cell abundanceImmune cell responsesImmunotherapeutic opportunities
2023
Type 2 Dendritic Cells Orchestrate a Local Immune Circuit to Confer Antimetastatic Immunity
Weizman O, Luyten S, Krykbaeva I, Song E, Mao T, Bosenberg M, Iwasaki A. Type 2 Dendritic Cells Orchestrate a Local Immune Circuit to Confer Antimetastatic Immunity. The Journal Of Immunology 2023, 210: 1146-1155. PMID: 36881866, PMCID: PMC10067787, DOI: 10.4049/jimmunol.2200697.Peer-Reviewed Original ResearchConceptsType 2 dendritic cellsMetastatic burdenImmune circuitsDendritic cellsConventional type 2 dendritic cellsSyngeneic murine melanomaNK cell compartmentImmune cell responsesColon cancer modelEarly metastatic seedingMetastatic controlTranscription factor IRF3DC populationsNK cellsProinflammatory cytokinesNucleic acid sensingPrimary tumorEffector responsesMetastatic spreadDisease outcomeIntracardiac injectionT cellsInitial immunityTissue-specific ablationCancer model
2022
RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice.
Joshi AA, Wu Y, Deng S, Preston-Hurlburt P, Forbes JM, Herold KC. RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice. Clinical Immunology 2022, 245: 109165. PMID: 36257528, DOI: 10.1016/j.clim.2022.109165.Peer-Reviewed Original ResearchConceptsXenograft rejectionIL-17AHumanized miceIL-1βT cellsImmune responseRAGE antagonistsAdaptive human immune responsesPD-1 expressionSkin graft rejectionHuman immune cell responsesImmune cell responsesHuman immune responseHuman immune cellsInnate immune responseAdvanced glycation endproductsInhibition of pathwaysSmall molecule antagonistsMultiple inflammatory processesAZ therapyRAGE antagonismGraft rejectionIL-23Serum levelsMedian time
2018
Advancing systems immunology through data-driven statistical analysis
Fong LE, Muñoz-Rojas AR, Miller-Jensen K. Advancing systems immunology through data-driven statistical analysis. Current Opinion In Biotechnology 2018, 52: 109-115. PMID: 29656236, PMCID: PMC6294467, DOI: 10.1016/j.copbio.2018.03.009.Peer-Reviewed Original Research
2017
Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils
Tovar C, Pye R, Kreiss A, Cheng Y, Brown G, Darby J, Malley R, Siddle H, Skjødt K, Kaufman J, Silva A, Baz Morelli A, Papenfuss A, Corcoran L, Murphy J, Pearse M, Belov K, Lyons A, Woods G. Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils. Scientific Reports 2017, 7: 43827. PMID: 28276463, PMCID: PMC5343465, DOI: 10.1038/srep43827.Peer-Reviewed Original ResearchConceptsEffective anti-tumor responseCancer cellsAnti-tumor immunityAnti-tumor responsesTumor diseaseDFTD cellsImmune-mediated regressionImmune cell infiltrationImmune cell responsesDevil facial tumour diseaseDFTD cancer cellsInduce humoral responsesTumor engraftmentMolecule expressionCell infiltrationDFTD tumorsHumoral responseAntibody responseMHC-IFacial tumour diseaseTumorCell responsesInfectious agentsImmunotherapyAllograft
2015
Assessing Host Immune Response to Dengue Virus Infection at Single‐Cell Resolution
Sulistijo E, Miller‐Jensen K. Assessing Host Immune Response to Dengue Virus Infection at Single‐Cell Resolution. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.571.26.Peer-Reviewed Original ResearchDengue shock syndromeDENV infectionDengue hemorrhagic feverDengue virusImmune responseDHF/dengue shock syndromeDengue feverSevere dengue hemorrhagic feverLevels of cytokinesDengue virus infectionInfected cellsSignaling profilesImmune cell responsesHost immune responseHost immune systemMosquito-borne pathogenNon-infected cellsInflammatory cytokinesShock syndromeDisease progressionVirus infectionHemorrhagic feverTherapeutic targetImmune systemSuppress progression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply